Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ACE | P12821 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 7/20 | 0.32 |
| ▸ | MMP2 | P08253 | 7/20 | 0.32 |
| ▸ | MMP3 | P08254 | 7/20 | 0.32 |
| ▸ | MMP7 | P09237 | 7/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.31 |
| ▸ | MME | P08473 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13201835 | 0.86 | KCNH3 (0.34) | MME | |
| SCHEMBL10424016 | 0.84 | FKBP4 (0.35) | CA1CA9 | |
| SCHEMBL14046514 | 0.80 | PIK3CD (0.31) | PIK3CD | |
| SCHEMBL291084 | 0.79 | FKBP1A (0.39) | FKBP1ACA1CA9 | |
| SCHEMBL11581437 | 0.77 | FKBP1A (0.38) | FKBP1ACA1CA9 | |
| SCHEMBL291957 | 0.76 | FKBP1A (0.37) | FKBP1A | |
| SCHEMBL14026095 | 0.75 | POLB (0.31) | — | |
| SCHEMBL18075754 | 0.75 | FKBP1A (0.36) | FKBP1ACA1CA9 | |
| SCHEMBL2484933 | 0.74 | FKBP1A (0.36) | FKBP1A | |
| SCHEMBL29935908 | 0.74 | FKBP1A (0.36) | FKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4400172-A2 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | Incyte Holdings Corporation (US) | 2024-07-17 | — | — | EP | disclosed |
| US-20240228508-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION | 2024-07-11 | — | — | US | disclosed |
| US-20240150327-A1 | BIPYRAZOLE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION | 2024-05-09 | — | — | US | disclosed |
| EP-4036088-B1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE HOLDINGS CORP (US) | 2024-04-03 | — | — | EP | disclosed |
| US-11905275-B2 | Bipyrazole derivatives as JAK inhibitors | INCYTE CORPORATION (US) | 2024-02-20 | — | — | US | disclosed |
| US-11851442-B2 | Tricyclic fused thiophene derivatives as JAK inhibitors | INCYTE CORPORATION (US) | 2023-12-26 | — | — | US | disclosed |
| EP-4275756-A2 | BIPYRAZOLE DERIVATIVES AS JAK INHIBITORS | Incyte Holdings Corporation (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-4268843-A2 | IMPROVED IL-6 ANTIBODIES | F. Hoffmann-La Roche Ltd (CH) | 2023-11-01 | — | — | EP | disclosed |
| EP-3786162-B1 | BIPYRAZOLE DERIVATIVES AS JAK INHIBITORS | INCYTE HOLDINGS CORP (US) | 2023-08-09 | — | — | EP | disclosed |
| US-11685731-B2 | Processes of preparing a JAK1 inhibitor | INCYTE CORPORATION (US) | 2023-06-27 | — | — | US | disclosed |
| US-20110086810-A1 | HYDROXYL, KETO, AND GLUCURONIDE DERIVATIVES OF 3-(4-(7H-PYRROLO[2,3-d] PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE | INCYTE CORPORATION (US) | 2011-04-14 | — | — | US | disclosed |
| WO-2011028685-A1 | HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-D]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2011-03-10 | — | — | WO | disclosed |
| US-20110059951-A1 | HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2011-03-10 | — | — | US | disclosed |
| EP-2288610-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | Incyte Corporation (US) | 2011-03-02 | — | — | EP | disclosed |
| WO-2010135650-A1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2010-11-25 | — | — | WO | disclosed |
| US-20100298334-A1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-20100113416-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | INCYTE CORPORATION | 2010-05-06 | — | — | US | disclosed |
| WO-2010039939-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | INCYTE CORPORATION (US) | 2010-04-08 | — | — | WO | disclosed |
| WO-2009114512-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2009-09-17 | — | — | WO | disclosed |
| US-20090233903-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11905275-B2 | Bipyrazole derivatives as JAK inhibitors | JAK1, JAK2, JAK3 | PIK3CD 214/4885FKBP1A 1045/4885LMNA 4851/4885 |
| US-20240228508-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | PIK3CD 24/4885FKBP1A 1172/4885LMNA 4881/4885 |
| US-20100298334-A1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK1, JAK3, JAK2 | PIK3CD 89/4885FKBP1A 1081/4885LMNA 4849/4885 |
| US-20100113416-A1 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES | JAK1, JAK3, JAK2 | PIK3CD 85/4885FKBP1A 2207/4885LMNA 4787/4885 |
| US-20110059951-A1 | HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | PIK3CD 48/4885FKBP1A 1324/4885LMNA 4745/4885 |
| US-11851442-B2 | Tricyclic fused thiophene derivatives as JAK inhibitors | JAK1, JAK3, JAK2 | PIK3CD 24/4885FKBP1A 1172/4885LMNA 4881/4885 |
| US-20110086810-A1 | HYDROXYL, KETO, AND GLUCURONIDE DERIVATIVES OF 3-(4-(7H-PYRROLO[2,3-d] PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE | UGT1A4, UGT1A3, UGT1A1 | PIK3CD 2662/4885FKBP1A 515/4885LMNA 4368/4885 |
| US-20240150327-A1 | BIPYRAZOLE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | PIK3CD 214/4885FKBP1A 1045/4885LMNA 4851/4885 |
| US-20090233903-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | PIK3CD 30/4885FKBP1A 834/4885LMNA 4853/4885 |
| US-11685731-B2 | Processes of preparing a JAK1 inhibitor | JAK1, JAK2, JAK3 | PIK3CD 21/4885FKBP1A 2581/4885LMNA 4714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.